How much did evolocumab lower LDL cholesterol in FOURIER?

Evolocumab reduced LDL cholesterol by 59% from a baseline median of 92 mg/dL, achieving a median on-treatment LDL of 30 mg/dL. This reduction was sustained throughout the 2.2-year median follow-up period.

Did FOURIER show a reduction in cardiovascular death?

No. Cardiovascular death occurred at nearly identical rates in both groups (1.8% vs. 1.7%, HR 1.05, p = 0.62). The benefit was concentrated in nonfatal MI, stroke, and coronary revascularization. The open-label extension suggested a possible late mortality benefit, but this requires cautious interpretation.

What is the number needed to treat for evolocumab based on FOURIER?

Over the 2.2-year trial duration, the NNT for the primary composite endpoint was approximately 67. For the key secondary endpoint of cardiovascular death, MI, or stroke, the NNT was approximately 67 as well. Longer treatment duration is expected to yield more favorable NNT values based on the trial's time-dependent benefit pattern.

Which patients benefit most from adding a PCSK9 inhibitor after FOURIER?

Patients with recent MI (within 2 years), polyvascular disease, elevated Lp(a), or diabetes with additional risk factors derived the greatest absolute benefit. The 2022 ACC Expert Consensus Decision Pathway uses these clinical features to prioritize PCSK9 inhibitor candidacy.

Did FOURIER find any safety concerns with very low LDL levels?

No. Even at LDL levels below 20 mg/dL, the trial detected no excess in neurocognitive adverse events, new-onset diabetes, hemorrhagic stroke, or cataracts. The EBBINGHAUS cognitive substudy confirmed no decline in executive function or memory at very low LDL levels.

How did FOURIER change the AHA/ACC cholesterol guidelines?

The 2018 AHA/ACC guideline incorporated PCSK9 inhibitors as a recommended option (Class IIa) for patients with clinical ASCVD whose LDL remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe. FOURIER was the primary evidence base for this recommendation.

Is evolocumab approved for primary prevention of cardiovascular disease?

No. FOURIER enrolled only patients with established atherosclerotic disease. There is no randomized outcomes trial supporting evolocumab for primary prevention. The FDA-approved indications cover adults with established ASCVD and adults with heterozygous or homozygous familial hypercholesterolemia.

How does FOURIER compare to ODYSSEY OUTCOMES with alirocumab?

Both trials showed approximately 15% relative risk reductions in MACE with a PCSK9 inhibitor added to statin therapy. ODYSSEY OUTCOMES enrolled only post-ACS patients and had a longer median follow-up (2.8 years). ODYSSEY OUTCOMES showed a nominal all-cause mortality reduction in a post-hoc analysis of highest-risk patients, a signal FOURIER did not detect.

Why is PCSK9 inhibitor prescribing still low despite FOURIER's results?

Insurance prior authorization requirements, high initial drug cost, administrative burden on prescribers, and patient reluctance toward injectable therapy all contribute. Even after price reductions and guideline endorsement, estimates suggest fewer than 30% of eligible patients in the U.S. receive a PCSK9 inhibitor.

What did the FOURIER open-label extension show?

FOURIER-OLE followed patients for up to 5 additional years and reported sustained LDL reduction, continued event reduction, and a nominal 15% lower rate of cardiovascular death in the original evolocumab group. However, the open-label design and differential dropout limit the strength of these conclusions.

What FOURIER Actually Changes in Clinical Practice

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Trial name: FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)
N: 27,564
Intervention: Evolocumab 140 mg every 2 weeks or 420 mg monthly (subcutaneous)
Comparator: Matching placebo
Duration: Median 2.2 years
Primary endpoint: Composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization
Key result: 15% relative risk reduction in primary composite endpoint (HR 0.85 to 95% CI 0.79-0.92, p < 0.001)

Why FOURIER Was Not Just Another Lipid Trial

Before FOURIER reported in March 2017, a stubborn clinical question remained unanswered: does lowering LDL cholesterol below the levels achievable with statins alone actually prevent heart attacks and strokes? Statin mega-trials had established the "lower is better" principle down to LDL levels around 50-70 mg/dL. But no randomized outcome trial had tested whether pushing LDL into the 20-30 mg/dL range with a non-statin agent would translate into fewer events.

FOURIER filled that gap using evolocumab, a fully human monoclonal antibody against PCSK9. The trial enrolled patients with clinically evident atherosclerotic cardiovascular disease (prior MI, prior stroke, or symptomatic peripheral artery disease) who were already on at least atorvastatin 20 mg or equivalent. This was not a statin-naive population. Every patient was already treated. The question was whether stacking a PCSK9 inhibitor on top of standard care would deliver measurable clinical benefit.

Methodology Details That Matter for Clinicians

The trial randomized patients 1:1 at 1,242 sites across 49 countries. Randomization was stratified by screening LDL cholesterol (<85 mg/dL vs. ≥85 mg/dL) and by region. Patients chose their own dosing schedule (biweekly or monthly), which is a practical design feature that mirrors real-world prescribing.

Baseline LDL was 92 mg/dL (median). By 48 weeks, evolocumab had driven LDL to a median of 30 mg/dL, a 59% reduction from baseline. The placebo group's LDL stayed at 90 mg/dL. This 60-point separation between arms persisted throughout follow-up and provides the pharmacologic substrate for interpreting every clinical endpoint in the trial.

One methodological detail that clinicians should note: the median follow-up was only 2.2 years. The investigators themselves acknowledged this was relatively short for a cardiovascular outcome trial. The IMPROVE-IT trial of ezetimibe, by comparison, followed patients for a median of 6 years. This compressed timeline has direct implications for interpreting the magnitude of benefit, a point we return to below.

The HealthRX Practice-Impact Framework

To assess whether a cardiovascular outcome trial should actually change prescribing, we apply four filters. Each addresses a different failure mode in translating trial data to clinic decisions.

Filter 1: Absolute risk reduction, not just relative. The primary composite endpoint occurred in 9.8% of the evolocumab group vs. 11.3% of the placebo group over 2.2 years. That is an absolute risk reduction of 1.5 percentage points, translating to a number needed to treat (NNT) of 67 over the trial's duration. For a drug that costs thousands of dollars annually, that NNT demands careful patient selection.

Filter 2: Component-level endpoint analysis. The 15% reduction in the five-component primary endpoint was driven primarily by reductions in MI (27% relative reduction, p < 0.001) and coronary revascularization (22% relative reduction, p < 0.001). Stroke fell by 21% (p = 0.01). Cardiovascular death showed no significant reduction (HR 1.05 to 95% CI 0.88-1.25). This pattern, events prevented but deaths not reduced, is the single most important nuance that press coverage of FOURIER consistently missed.

Filter 3: Time-dependent benefit accrual. A pre-specified landmark analysis split outcomes into the first 12 months and beyond 12 months. During year one, the key secondary endpoint (cardiovascular death, MI, or stroke) fell by 12%. After year one, the reduction deepened to 25%. This progressive separation of the Kaplan-Meier curves suggests that the 2.2-year median follow-up may have underestimated the drug's full potential. Longer exposure likely yields larger absolute benefit.

Filter 4: Safety floor. Injection-site reactions were more common with evolocumab (2.1% vs. 1.6%). No significant excess of neurocognitive events, new-onset diabetes, myalgia, or cataracts appeared. The EBBINGHAUS substudy, which used formal neuropsychological testing in 1,974 patients, found no cognitive signal even at very low LDL levels. This was a genuine concern before the trial reported, and FOURIER's clean safety data helped resolve it.

Results: The Numbers Competitors Omit

| Endpoint | Evolocumab (%) | Placebo (%) | HR (95% CI) | p-value | |---|---|---|---|---| | Primary composite (5-point MACE) | 9.8 | 11.3 | 0.85 (0.79-0.92) | <0.001 | | Key secondary (CV death, MI, stroke) | 5.9 | 7.4 | 0.80 (0.73-0.88) | <0.001 | | Myocardial infarction | 3.4 | 4.6 | 0.73 (0.65-0.82) | <0.001 | | Stroke | 1.5 | 1.9 | 0.79 (0.66-0.95) | 0.01 | | Coronary revascularization | 5.5 | 7.0 | 0.78 (0.71-0.86) | <0.001 | | Cardiovascular death | 1.8 | 1.7 | 1.05 (0.88-1.25) | 0.62 | | All-cause death | 3.2 | 3.1 | 1.04 (0.91-1.19) | 0.56 |

The dissociation between MI/stroke reduction and cardiovascular mortality is not unique to FOURIER. IMPROVE-IT showed the same pattern at 1 year but eventually demonstrated mortality separation at 7 years. Whether FOURIER would have shown a mortality benefit with longer follow-up remains debated. The open-label extension, FOURIER-OLE, provided 5 additional years of data and reported a nominal 15% reduction in cardiovascular death among patients originally randomized to evolocumab, though the open-label design limits causal inference.

Which Guidelines Actually Changed

FOURIER's 2017 publication triggered a cascade of guideline revisions:

2018 AHA/ACC Cholesterol Guideline. For the first time, the American Heart Association and American College of Cardiology formally incorporated PCSK9 inhibitors into their treatment algorithm. Patients with clinical ASCVD and LDL ≥70 mg/dL on maximally tolerated statin plus ezetimibe became candidates for a PCSK9 inhibitor. The guideline explicitly cited FOURIER as the evidence base for this recommendation (Class IIa, Level A).

2019 ESC/EAS Dyslipidemia Guideline. The European Society of Cardiology went further, setting an LDL target of <55 mg/dL for very-high-risk patients and <40 mg/dL for those with a second vascular event within 2 years. PCSK9 inhibitors became the recommended third-line agent after statin plus ezetimibe. This aggressive target framework was built directly on FOURIER and ODYSSEY OUTCOMES data.

2022 ACC Expert Consensus Decision Pathway. Updated to include a "risk enhancer" framework that specifically identifies patients most likely to benefit from PCSK9 inhibition: those with multiple prior events, multivessel CAD, elevated Lp(a), or diabetes with additional risk factors.

Who Benefits Most (and Who Probably Does Not)

FOURIER enrolled a broad population, but subgroup analyses and post-hoc studies reveal where the benefit concentrates:

Higher baseline risk, larger absolute benefit. Patients with a recent MI (within 2 years) had greater absolute risk reduction than those with remote events. Patients with peripheral artery disease, polyvascular disease, or diabetes derived larger absolute gains, consistent with the principle that high-risk denominators amplify treatment effects.

Patients with very high Lp(a). A post-hoc analysis showed that patients in the top Lp(a) tertile had a 23% relative reduction in coronary events with evolocumab, compared with a smaller benefit in low-Lp(a) patients. This is biologically plausible because PCSK9 inhibitors modestly reduce Lp(a) by 20-30%, an effect that statins do not provide.

Primary prevention patients. FOURIER enrolled only secondary prevention patients. There is no randomized trial evidence supporting evolocumab for primary prevention, and the NNT calculations in lower-risk populations would likely be unfavorable relative to cost.

Statin-intolerant patients. While not the primary FOURIER population, real-world registry data suggests that PCSK9 inhibitor monotherapy in truly statin-intolerant patients produces LDL reductions of 50-60%. The Repatha prescribing information includes this population in its indication.

Limitations the Authors Acknowledged

The FOURIER investigators were transparent about several constraints that clinicians should weigh:

Short follow-up. At 2.2 years, the trial may have captured only the early phase of a time-dependent benefit curve. The open-label extension partially addresses this, but with the caveats inherent to unblinded data.
No cardiovascular mortality reduction. The investigators noted that the event rate for CV death was lower than projected, reducing statistical power for this individual endpoint.
Population homogeneity. The trial was 85% white and 75% male. Enrollment from regions with different healthcare systems and baseline treatment intensity may limit generalizability.
Cost-effectiveness was not assessed within the trial. At its original list price (~$14,000/year), evolocumab failed most cost-effectiveness thresholds. Subsequent price reductions (to roughly $5,850/year) and Amgen's outcomes-based contracts have improved the pharmacoeconomic profile, but access barriers persist through prior authorization requirements.

What This Means for Patients Who Differ From the Trial Population

FOURIER's enrollment criteria were specific: established ASCVD, age 40-85, LDL ≥70 mg/dL (or non-HDL ≥100 mg/dL) on optimized statin. Clinicians frequently ask about extrapolation beyond these boundaries.

For patients under 40 with familial hypercholesterolemia, the trial does not directly apply, but mechanistic reasoning and registry data support PCSK9 inhibitor use. For patients over 85, the absence of trial data and increasing frailty-related competing risks make the risk-benefit calculation less certain. For patients with heart failure or reduced ejection fraction (who were excluded from FOURIER), no randomized evidence supports routine PCSK9 inhibitor use.

The most common real-world scenario that FOURIER did not directly test is the patient who cannot tolerate any statin dose. These patients were a small fraction of the trial population, and while the drug's LDL-lowering mechanism is statin-independent, the magnitude of cardiovascular risk reduction as monotherapy has not been established in a dedicated outcomes trial.

The Access Gap Between Evidence and Practice

Despite clear guideline endorsement, PCSK9 inhibitor prescribing remains a fraction of eligible patients. Insurance prior authorization rejection rates exceeded 50% in the years immediately following FOURIER's publication. Even with price cuts and expanded coverage criteria, many clinicians report that the administrative burden of prescribing a PCSK9 inhibitor, which can require multiple appeals and peer-to-peer reviews, discourages initiation.

This is the gap where FOURIER's clinical implications are most incomplete. The trial proved efficacy. Guidelines incorporated the evidence. But the final mile, getting the drug to the patients who match the trial population, remains a systems-level failure that no randomized trial can fix.

Frequently asked questions

›

References

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. PubMed
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379(22):2097-2107. PubMed
O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease (FOURIER-OLE). Circulation. 2022;146(15):1109-1119. PubMed
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. PubMed
Evolocumab (Repatha) Prescribing Information. Amgen Inc. Revised 2021. FDA Label
Szarek M, Bittner VA, Gorcyca K, et al. Lipoprotein(a) lowering by evolocumab and clinical outcomes. Eur Heart J. 2020;41(32):3049-3056. PubMed